Fed Circuit affirms cancellation of Anacor antifungal patents
01-09-2020
Former Genentech employee cuts plea deal with FBI in trade secrets case
16-01-2020
UK court overturns Genentech patent, cites Brexit in CJEU referral
01-03-2019
Sundry Photography / Shutterstock.com
Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Genentech, Hemlibra, patent, Takeda, infringement, haemophilia, Federal Circuit, claim construction, Baxalta
